Pharmaceutical Companies Among the Leaders in Keeping Construction Industry Humming
11-17-2009
America's Pharmaceutical companies are doing their share to keep the construction industry working as the U.S. emerges from recession. According to Engineering News Record, a McGraw-Hill publication that tracks construction spending, eight pharmaceutical companies have more than $1.3 billion worth of construction projects in the works.
That includes:
| Johnson & Johnson |
$3,552 billion |
| Pfizer Inc. |
$1,804 billion |
| Wyeth |
$1,403.2 billion |
| Eli Lilly and Co. |
$1,098.3 billion |
| Schering-Plough |
$1,008 billion |
| Merck & Co. |
$871 billion |
| Amgen Inc. |
$826 billion |
By comparison, Johnson & Johnson will spend more than three times the entire top 10 health services firms for construction in progress. Likewise, the top eight pharmaceutical companies in terms of construction are spending almost 40 percent more than the top 10 electronic firms; and 46 percent more than the top 10 communications firms.